🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

J. B. Chemicals & Pharmaceuticals Limited JBCHEPHARM NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.jbpharma.com

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

READ MORE ›
₹2,167.40
+29.57% 1Y

Market & Price

Market Cap
₹34,799.49 Cr
Current Price
₹2,167.40
High / Low (52W)
₹2,228.40 / ₹1,591.77
Beta
-0.04

Valuation

Stock P/E
48.78
Industry PE
37.60
Forward P/E
29.73
PEG Ratio
-
Book Value
₹243.38
Price to Book
8.91
P/S
8.39
EV/EBITDA
30.79
Dividend Yield
0.86%

Profitability & Returns

ROCE
21.88%
ROE
18.69%
ROA
12.48%
Profit Margin
17.11%
Op Margin
16.48%
EPS (Latest Qtr)
₹6.32
EPS (TTM)
₹44.43

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
3.45
Current Ratio
4.92
Debt
₹3.59 Cr
Total Assets
₹4,968.65 Cr
Current Assets
₹2,909.37 Cr
Working Capital
₹2,318.21 Cr

Ownership

Promoter Holding
49.23%
Chg in Prom Hold
-
FII / Inst Holding
30.15%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹33,581.74 Cr
Total Revenue (TTM)
₹4,147.79 Cr
EBITDA
₹1,090.67 Cr
Free Cash Flow
₹506.48 Cr
Operating Cash Flow
₹703.92 Cr
Shares Outstanding
₹16.06 Cr
Gross Margin
67.77%
Payout Ratio
44.32%

Growth (CAGR)

Revenue 5Y
9.36%
Profit 5Y
20.07%
Revenue (YoY)
-4.80%
Earnings (YoY)
-31.00%

PROS

  • Healthy ROCE of 21.9%.
  • Profit CAGR of 20.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JBCHEPHARM J. B. Chemicals & Pharmaceuticals Limited NIFTY_SMALLNSEPHARMA 2,167.40 48.78 ₹34,799.49 Cr 0.86% 21.88% 18.69% 9.36% 20.07%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 949.48 Cr1,093.94 Cr1,084.90 Cr1,064.72 Cr904.23 Cr
Cost of Revenue 321.64 Cr347.10 Cr345.49 Cr329.43 Cr274.25 Cr
Gross Profit 627.84 Cr746.84 Cr739.41 Cr735.29 Cr629.98 Cr
Operating Expenses 447.84 Cr488.67 Cr474.25 Cr484.82 Cr478.86 Cr
Operating Income 180.00 Cr258.17 Cr265.16 Cr250.47 Cr151.12 Cr
EBITDA 240.92 Cr315.42 Cr324.94 Cr314.10 Cr185.93 Cr
Interest Expense 1.45 Cr1.11 Cr1.35 Cr1.88 Cr1.23 Cr
Pretax Income 193.03 Cr271.61 Cr279.15 Cr266.87 Cr134.69 Cr
Tax Provision 47.34 Cr69.23 Cr71.33 Cr68.98 Cr33.32 Cr
Net Income 145.69 Cr202.38 Cr207.82 Cr197.89 Cr101.37 Cr
Diluted EPS 9.1712.7513.0812.456.32

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -3,116.51 Cr3,447.67 Cr3,862.04 Cr4,076.20 Cr
Cost of Revenue -1,184.80 Cr1,202.95 Cr1,340.32 Cr1,324.30 Cr
Gross Profit -1,931.71 Cr2,244.72 Cr2,521.73 Cr2,751.89 Cr
Operating Expenses -1,344.22 Cr1,492.09 Cr1,667.21 Cr1,851.02 Cr
Operating Income -587.49 Cr752.63 Cr854.52 Cr900.88 Cr
EBITDA -705.05 Cr933.48 Cr1,069.12 Cr1,140.28 Cr
Interest Expense -35.41 Cr43.65 Cr10.69 Cr5.44 Cr
Pretax Income -555.23 Cr751.51 Cr887.39 Cr952.34 Cr
Tax Provision -145.23 Cr198.88 Cr227.81 Cr242.86 Cr
Net Income -409.84 Cr552.63 Cr659.58 Cr709.47 Cr
Diluted EPS 24.9126.1734.8541.56-

Compounded Sales Growth

5 Years:9.36%
1 Year:-4.80%

Compounded Profit Growth

5 Years:20.07%
1 Year:-31.00%

Stock Price Performance

1 Year:+29.57%
6 Months:+24.21%
3 Months:+5.89%
1 Month:+5.15%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -3,553.87 Cr3,994.13 Cr4,273.78 Cr4,968.65 Cr
Current Assets -1,528.03 Cr1,853.35 Cr1,922.74 Cr2,909.37 Cr
Cash & Equivalents -76.93 Cr88.22 Cr115.09 Cr110.18 Cr
Inventory -430.48 Cr502.51 Cr528.96 Cr683.40 Cr
Receivables -575.80 Cr686.92 Cr815.38 Cr780.91 Cr
Total Liabilities -1,073.52 Cr1,070.80 Cr840.46 Cr809.43 Cr
Current Liabilities -554.45 Cr868.23 Cr632.34 Cr591.16 Cr
Long Term Debt -383.22 Cr23.64 Cr0-
Total Debt -572.45 Cr377.66 Cr27.89 Cr3.59 Cr
Total Equity -2,480.35 Cr2,923.33 Cr3,433.32 Cr4,159.22 Cr
Shares Outstanding -15.48 Cr15.52 Cr15.57 Cr16.06 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -625.61 Cr800.61 Cr902.45 Cr703.92 Cr
Investing Cash Flow --961.79 Cr-403.83 Cr-295.90 Cr-585.88 Cr
Financing Cash Flow -356.54 Cr-385.49 Cr-579.67 Cr-123.10 Cr
Capital Expenditure --764.95 Cr-261.37 Cr-120.31 Cr-83.19 Cr
Free Cash Flow --139.33 Cr539.24 Cr782.14 Cr620.73 Cr
Net Change in Cash -20.36 Cr11.30 Cr26.88 Cr-5.05 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -62.0%65.1%65.3%67.5%
Operating Margin % -18.9%21.8%22.1%22.1%
Net Margin % -13.2%16.0%17.1%17.4%
ROE % -16.5%18.9%19.2%17.1%
ROCE % -19.6%24.1%23.5%20.6%

Shareholding Pattern

Insiders
49.23%
Institutions
30.15%
Public Float
59.38%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JBCHEPHARM

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space